In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Aptose Biosciences (APTO – Research Report), with a price target of $5.00. The company’s shares
In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Aptose Biosciences (APTO – Research Report), with a price target of $5.00. The company’s shares
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ATAI Life Sciences (ATAI – Research Report), Alnylam Pharma (ALNY – Research Report) and Aptose Biosciences (APTO – Research Report) with bullish sentiments.
ATAI Life Sciences (ATAI)
In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on ATAI Life Sciences, with a price target of $11.00. The company’s shares closed last Wednesday at $1.79.
According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ATAI Life Sciences with a $15.50 average price target, a 761.1% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
Alnylam Pharma (ALNY)
In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma, with a price target of $283.00. The company’s shares closed last Wednesday at $154.39, close to its 52-week low of $143.52.
According to TipRanks.com, Ijem is a 5-star analyst with an average return of
Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $219.32.
Aptose Biosciences (APTO)
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Aptose Biosciences, with a price target of $15.00. The company’s shares closed last Wednesday at $1.50, close to its 52-week low of $1.36.
According to TipRanks.com, Newman is a 5-star analyst with an average return of
Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $12.00, a 700.0% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATAI:
Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Aptose Biosciences (APTO – Research Report). The associated price target is $5.00. Soumit Roy has given his Buy rating
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aptose Biosciences (APTO – Research Report), Syndax Pharmaceuticals (SNDX – Research Report) and Delcath Systems (DCTH – Research Report) with bullish sentiments.
Aptose Biosciences (APTO)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Aptose Biosciences, with a price target of $23.00. The company’s shares closed last Tuesday at $1.60, close to its 52-week low of $1.36.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aptose Biosciences with a $14.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Syndax Pharmaceuticals (SNDX)
In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Syndax Pharmaceuticals, with a price target of $41.00. The company’s shares closed last Tuesday at $21.44.
According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Syndax Pharmaceuticals with a $34.00 average price target, implying a 50.0% upside from current levels. In a report issued on March 20, J.P. Morgan also maintained a Buy rating on the stock with a $34.00 price target.
Delcath Systems (DCTH)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Delcath Systems, with a price target of $20.00. The company’s shares closed last Tuesday at $4.61.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Delcath Systems with a $18.00 average price target, which is a 293.9% upside from current levels. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $16.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APTO:
Aptose Biosciences (TSE:APS) has released an update. Aptose Biosciences has announced positive results for tuspetinib, highlighting its safety and effectiveness across multiple mutational subtypes in AML, leading to a new